Eisai Inc.
Kamisu, Japan
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Eisai Inc. is a clinical trial sponsor based in Kamisu, Japan. It has 30 active clinical trials with 22,700 planned participants, across 15 therapeutic areas. Since 2021 it has completed 133 trials and stopped 19 early. Its FDA record on file shows 2 inspections.
Trial track record · since 2021
FDA record
Recent FDA actions
Financials
No SEC filings under this name. The company is private, listed abroad, or files under a parent.
Fundraising
No SEC Form D filings under this name. A private round is only public when the company files one.
Pipeline · 30 active trials
| Stage | Trial | Status |
|---|---|---|
On the market · 11 products
- LEQEMBI lecanemab-irmb · BLA 761269 · prescription
- LENVIMA lenvatinib mesylate · NDA 206947 · prescription
- BANZEL rufinamide · NDA 021911 · prescription
- LEQEMBI IQLIK lecanemab-irmb · BLA 761375 · prescription
- BANZEL rufinamide · NDA 201367 · prescription
- HALAVEN eribulin mesylate · NDA 201532 · prescription
- FYCOMPA perampanel · NDA 202834 · prescription
- DAYVIGO lemborexant · NDA 212028 · prescription
- ARICEPT donepezil hydrochloride · NDA 020690 · prescription
- FYCOMPA perampanel · NDA 208277 · prescription
- ARICEPT donepezil hydrochloride · NDA 022568 · prescription
Questions about Eisai Inc
No warning letter naming Eisai Inc is on file. FDA has published 2 inspection classifications naming it.
FDA has posted 2 inspection classifications naming Eisai Inc (2 VAI). The latest inspection ended on 2026-07-24 and was classified VAI (voluntary action indicated). FDA posts a classification after its review, often months after the inspection ended.
Eisai Inc is lead sponsor of 30 active clinical trials on ClinicalTrials.gov, with 22,700 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 133 trials and stopped 19 early.
Eisai Inc is based in Kamisu, Japan. The address is the one on its FDA records or ClinicalTrials.gov registrations, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Eisai Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-14.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Products come from FDA's drug application database and, for vaccines, cell and gene therapies and blood products, FDA's Purple Book of licensed biologics; checked 2026-10-02.
Approve Suite is not affiliated with Eisai Inc.. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.